Ariel Hurley - 15 Dec 2023 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Role
PRINCIPAL ACCOUNTING OFFICER
Signature
/s/ Melissa Masse, Attorney-in-Fact
Issuer symbol
BPMC
Transactions as of
15 Dec 2023
Net transactions value
-$323,313
Form type
4
Filing time
19 Dec 2023, 16:05:13 UTC
Previous filing
19 Mar 2024
Next filing
26 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Options Exercise $3,416 +1,827 +13% $1.87* 16,411 15 Dec 2023 Direct F1
transaction BPMC Common Stock Sale $154,107 -1,827 -11% $84.35 14,584 15 Dec 2023 Direct F1
transaction BPMC Common Stock Options Exercise $3,416 +1,827 +13% $1.87* 16,411 15 Dec 2023 Direct F1
transaction BPMC Common Stock Sale $154,107 -1,827 -11% $84.35 14,584 15 Dec 2023 Direct F1
transaction BPMC Common Stock Sale $21,931 -260 -1.8% $84.35 14,324 15 Dec 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Options Exercise $0 -3,654 -100% $0.000000* 0 15 Dec 2023 Common Stock 3,654 $1.87 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Effected pursuant to a trading plan adopted on September 13, 2023 in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 This option was granted on October 8, 2014 and is fully vested as of the transaction date.